Evidence map›Paper›PMID 42124568›Full record

ArticlebioRxiv : the preprint server for biology2026

mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.

Claudia Gentile, William W Feng, Sean M Lenahan, Alexander W Ying, Daren C Card, Florence T H Wu, Nhu-An Pham, Nikolina Radulovich, Pinjiang Mary Cao, Katrina Hueniken and 16 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Claudia GentileDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 02215.
William W FengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8976-5020
Sean M LenahanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander W YingDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 02215.ORCID 0009-0005-9826-0613
Daren C CardDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 02215.ORCID 0000-0002-1629-5726
Florence T H WuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-6439-4606
Nhu-An PhamPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Nikolina RadulovichPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8224-7263
Pinjiang Mary CaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Katrina HuenikenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-1376-8046
Quan LiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ming-Sound TsaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-9160-5405
Joseph KuleszaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Madeline M HinkleyDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 02215.
Lishu LiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0001-9572-4524
Jeanelle A TsaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0006-3367-8426
Jens KöhlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Francesco FacchinettiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jiaqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Caitlyn WestonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marie-Anaïs LocquetDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3594-7128
Kenneth NgoBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-5511-2825
Prafulla C GokhaleBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1974-5921
Adrian G SacherPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-7865-2701
Pasi A JänneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-7821-4928
Cigall KadochDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA 02215.ORCID 0000-0002-4058-5985

Funding

Development of Combination Therapies to Delay/Prevent Acquired Drug ResistanceR35CA220497 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2018 to 2024
$7.2M
High-Throughput DNA Sequencing SystemS10OD036228 · OD · DANA-FARBER CANCER INST · PI HERBERT, ZACHARY T · 2024 to 2024
$1.0M
NCI NIH HHS R35 CA220497NIH HHS S10 OD036228
6 · The paper itself

Abstract

Targeted therapies for

Identifiers

PMID42124568
PMCPMC13160128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.